Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172181 | 1.00 | HTR2C (0.49) | HTR2CDRD2HTR2AHTR2BCCR1 | |
| Hydrochloric Acid SCHEMBL10502464 | 0.98 | HTR2C (0.48) | HTR2CDRD2HTR2AHTR2BCCR1 | |
| SCHEMBL31059137 | 0.91 | HTR2C (0.45) | HTR2CDRD2HTR2AHTR2BCCR1 | |
| SCHEMBL4222971 | 0.91 | HTR2C (0.45) | HTR2CDRD2HTR2AHTR2BCCR1 | |
| SCHEMBL4220742 | 0.87 | HTR2C (0.49) | HTR2CDRD2HTR2AHTR2BMAPT | |
| SCHEMBL864191 | 0.87 | HTR2C (0.49) | HTR2CDRD2HTR2AHTR2BMAPT | |
| Hydrochloric Acid SCHEMBL4221293 | 0.86 | HTR2C (0.48) | HTR2CDRD2HTR2AHTR2BMAPT | |
| Hydrochloric Acid SCHEMBL11241821 | 0.86 | HTR2C (0.48) | HTR2CDRD2HTR2AHTR2BMAPT | |
| SCHEMBL13910961 | 0.85 | DRD2 (0.47) | DRD2CCR1KCNH2 | |
| SCHEMBL863813 | 0.82 | HTR2C (0.50) | HTR2CDRD2HTR2AHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007408-A2 | INTERMEDIATES 2-(2-CHLORO-5-HYDROXY-4-METHYLCARBAMOYLPHENOXY)-2-METHYLPROPIONIC ACID TERT-BUTYL ESTER AND GLYCIDYL BENZENE SULFONATES OR SALTS THEREOF AND THE PROCESS FOR PREPARATION OF SAID INTERMEDIATES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| EP-2120935-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-2069355-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005061499-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005054249-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005049620-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| US-4420485-A | HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0004951-B1 | N-(3-BENZOYLPROPYL)-SPIRO-(DIHYDROBENZOFURANPIPERIDINES AND -PYRROLIDINES), DERIVATIVES THEREOF, METHODS FOR THEIR PREPARATION AND THEIR USE FOR MEDICINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-13 | — | — | EP | disclosed |
| EP-0004951-A1 | N-(3-benzoylpropyl)-spiro-(dihydrobenzofuranpiperidines and -pyrrolidines), derivatives thereof, methods for their preparation and their use for medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-31 | — | — | EP | disclosed |
| US-4166120-A | Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines | AMERICAN HOECHST CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | GRK5, ADRB2, GRK2 | HTR2C 1320/4885DRD2 2276/4885HTR2A 1548/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | HTR2C 1811/4885DRD2 22/4885HTR2A 1145/4885 |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ACKR3, CCR2, CCR5 | HTR2C 1074/4885DRD2 280/4885HTR2A 959/4885 |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | HTR2C 1980/4885DRD2 606/4885HTR2A 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.